Higher concentrations of the Erk1/2 inhibitor U0126 were required to reduce proliferation in T2D VSMCs compared to normoglycemic mice to levels below control conditions without PDGF (Figure 5C,D). Here, MAPK3 is linked to type 2 diabetes mellitus.